Key Words: Mesenchymal stem cells; Non-alcoholic fatty liver disease; Therapeutic potential; Liver fibrosis; Regenerative medicine; Stem cell therapy; Inflammation; Clinical trials
Core Tip: Mesenchymal stem cells (MSCs) constitute a promising therapy for non-alcoholic fatty liver disease. Expanding upon insights from the forthcoming study by Jiang et al. MSCs demonstrate potent immunomodulatory and anti-inflammatory effects and can promote liver tissue regeneration. Addressing challenges such as MSC heterogeneity and ensuring long-term safety through standardized protocols are crucial to harnessing the full therapeutic potential of MSCs in clinical settings.
- Citation: Cheng CH, Hao WR, Cheng TH. Mesenchymal stem cells: A promising therapeutic avenue for non-alcoholic fatty liver disease. World J Stem Cells 2024; 16(8): 780-783
- URL: https://www.wjgnet.com/1948-0210/full/v16/i8/780.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i8.780